The Centers for Medicare & Medicaid Services (CMS) has said it will announce the next 15 drugs in scope for the second round ...

Meanwhile, the time has come to turn to our ever-growing to-do list. Sound familiar? So here are some items of interest. Have a great day, everyone. … Hims & Hers Health plans to sell compounded ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti ... You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Specifically, on the key price-to-earnings ratio (P/E) measurement of relative stock valuation, it trades at just 16.7. This is at the bottom of the list of its peers ... is litigation over GSK’s ...

The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the ...

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...

GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma: London, UK Saturday, September 14, 2024, 0 ...

In this article, we are going to take a look at where GSK plc ... For our list of best pharma stocks to buy according to short sellers, we ranked specialty and general drug manufacturers with ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...